Agilent Technologies (NYSE:A) Price Target Increased to $145.00 by Analysts at Barclays

Agilent Technologies (NYSE:A) had its price objective hoisted by Barclays from $135.00 to $145.00 in a report issued on Tuesday, Benzinga reports. They currently have an underweight rating on the medical research company’s stock.

A number of other equities analysts also recently issued reports on A. UBS Group increased their price objective on Agilent Technologies from $141.00 to $150.00 and gave the stock a neutral rating in a report on Thursday, August 22nd. Wells Fargo & Company initiated coverage on shares of Agilent Technologies in a research note on Tuesday, August 27th. They issued an overweight rating and a $157.00 price target for the company. Citigroup boosted their price objective on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a buy rating in a research note on Thursday, August 22nd. Stifel Nicolaus reaffirmed a buy rating and set a $151.00 target price on shares of Agilent Technologies in a research note on Monday, August 26th. Finally, Bank of America boosted their price target on Agilent Technologies from $140.00 to $147.00 and gave the stock a neutral rating in a research report on Thursday, August 22nd. One analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average price target of $144.36.

Agilent Technologies Trading Up 0.2 %

NYSE:A opened at $144.58 on Tuesday. The company has a 50-day moving average price of $140.87 and a 200-day moving average price of $138.86. The stock has a market cap of $42.18 billion, a price-to-earnings ratio of 34.18, a P/E/G ratio of 6.96 and a beta of 1.05. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36. Agilent Technologies has a 12 month low of $96.80 and a 12 month high of $155.35.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The business had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same period in the previous year, the firm posted $1.43 EPS. The business’s revenue was down 5.6% on a year-over-year basis. Equities analysts predict that Agilent Technologies will post 5.24 EPS for the current year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st will be issued a $0.236 dividend. The ex-dividend date is Tuesday, October 1st. This represents a $0.94 annualized dividend and a yield of 0.65%. Agilent Technologies’s payout ratio is 22.22%.

Insiders Place Their Bets

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $140.00, for a total transaction of $274,120.00. Following the sale, the chief executive officer now owns 26,076 shares of the company’s stock, valued at $3,650,640. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $140.00, for a total value of $274,120.00. Following the sale, the chief executive officer now owns 26,076 shares of the company’s stock, valued at approximately $3,650,640. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,953 shares of company stock valued at $2,013,630. 0.33% of the stock is owned by insiders.

Hedge Funds Weigh In On Agilent Technologies

Several institutional investors have recently made changes to their positions in A. Keystone Wealth Services LLC bought a new position in Agilent Technologies in the 3rd quarter worth $285,000. Occidental Asset Management LLC increased its position in Agilent Technologies by 3.9% in the third quarter. Occidental Asset Management LLC now owns 21,214 shares of the medical research company’s stock worth $3,150,000 after buying an additional 800 shares in the last quarter. Creative Planning increased its position in Agilent Technologies by 5.9% in the third quarter. Creative Planning now owns 44,910 shares of the medical research company’s stock worth $6,668,000 after buying an additional 2,498 shares in the last quarter. Wesbanco Bank Inc. raised its stake in shares of Agilent Technologies by 8.4% in the third quarter. Wesbanco Bank Inc. now owns 2,455 shares of the medical research company’s stock worth $365,000 after buying an additional 190 shares during the period. Finally, Gibson Capital LLC purchased a new position in shares of Agilent Technologies during the 3rd quarter valued at about $192,000. Institutional investors own 87.42% of the company’s stock.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.